321 related articles for article (PubMed ID: 33842000)
1. Update on systemic treatment for newly diagnosed inflammatory breast cancer.
Chainitikun S; Saleem S; Lim B; Valero V; Ueno NT
J Adv Res; 2021 Mar; 29():1-12. PubMed ID: 33842000
[TBL] [Abstract][Full Text] [Related]
2. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
3. What is the best systemic treatment for newly diagnosed inflammatory breast cancer?-a narrative review.
Chainitikun S; Mingmalairak S; Parinyanitikul N
Chin Clin Oncol; 2021 Dec; 10(6):55. PubMed ID: 34670376
[TBL] [Abstract][Full Text] [Related]
4. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
Chainitikun S; Espinosa Fernandez JR; Long JP; Iwase T; Kida K; Wang X; Saleem S; Lim B; Valero V; Ueno NT
PLoS One; 2021; 16(4):e0250057. PubMed ID: 33861773
[TBL] [Abstract][Full Text] [Related]
5. IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model.
Dawood S; Cristofanilli M
J Natl Cancer Inst Monogr; 2015 May; 2015(51):56-9. PubMed ID: 26063888
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
7. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
[TBL] [Abstract][Full Text] [Related]
8. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
Dawood S; Merajver SD; Viens P; Vermeulen PB; Swain SM; Buchholz TA; Dirix LY; Levine PH; Lucci A; Krishnamurthy S; Robertson FM; Woodward WA; Yang WT; Ueno NT; Cristofanilli M
Ann Oncol; 2011 Mar; 22(3):515-523. PubMed ID: 20603440
[TBL] [Abstract][Full Text] [Related]
9. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.
Tsai CJ; Li J; Gonzalez-Angulo AM; Allen PK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Yang W; Cristofanilli M; Valero V; Buchholz TA
Am J Clin Oncol; 2015 Jun; 38(3):242-7. PubMed ID: 23648437
[TBL] [Abstract][Full Text] [Related]
10. Development of CNS metastases and survival in patients with inflammatory breast cancer.
Uemura MI; French JT; Hess KR; Liu D; Raghav K; Hortobagyi GN; Arun BK; Valero V; Ueno NT; Alvarez RH; Woodward WA; Debeb BG; Moulder SL; Lim B; Tripathy D; Ibrahim NK
Cancer; 2018 Jun; 124(11):2299-2305. PubMed ID: 29579338
[TBL] [Abstract][Full Text] [Related]
11. What is the best treatment recommendation for HER2+ IBC with residual disease?-a narrative review.
Zakon DB; Valero V
Chin Clin Oncol; 2021 Dec; 10(6):59. PubMed ID: 35016513
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.
Dawood S; Gong Y; Broglio K; Buchholz TA; Woodward W; Lucci A; Valero V; Gonzalez-Angulo AM; Hortobagyi GN; Cristofanilli M
Breast J; 2010; 16(5):529-32. PubMed ID: 20626396
[TBL] [Abstract][Full Text] [Related]
15. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
16. Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Van Berckelaer C; Rypens C; van Dam P; Pouillon L; Parizel M; Schats KA; Kockx M; Tjalma WAA; Vermeulen P; van Laere S; Bertucci F; Colpaert C; Dirix L
Breast Cancer Res; 2019 Feb; 21(1):28. PubMed ID: 30777104
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory breast cancer: what progress have we made?
Dawood S; Cristofanilli M
Oncology (Williston Park); 2011 Mar; 25(3):264-70, 273. PubMed ID: 21548470
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.
Kharel Z; Nemer OP; Xi W; Upadhayaya B; Falkson CI; O'Regan RM; Dhakal A
Breast Dis; 2022; 41(1):255-260. PubMed ID: 35599460
[TBL] [Abstract][Full Text] [Related]
20. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Gonçalves A; Pierga JY; Ferrero JM; Mouret-Reynier MA; Bachelot T; Delva R; Fabbro M; Lerebours F; Lotz JP; Linassier C; Dohollou N; Eymard JC; Leduc B; Lemonnier J; Martin AL; Boher JM; Viens P; Roché H
Ann Oncol; 2015 Aug; 26(8):1692-7. PubMed ID: 25943350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
